HIV Infections Clinical Trial
Official title:
Optimizing Strategies for Universal HIV Testing (The USHER Trial)
This study will compare the effectiveness of two different approaches to providing routine HIV counseling, testing, and referral services in an urban hospital emergency department setting.
About 25% of HIV infected people do not know that they are infected. These people lack
medical care that could prolong their lives and access to counseling services that could
prevent further spread of HIV. With so many people unaware of their HIV status, there is a
clear need for more readily available HIV counseling, testing, and referral services
throughout the United States. The Centers for Disease Control and Prevention (CDC)
recommends routine HIV testing in U.S. hospitals in which HIV infected patients make up at
least 1% of the total patient population for that hospital. However, routine HIV testing in
such hospitals is rarely carried out, which might be because the CDC has not specified who
should perform routine HIV testing. The purpose of this study is to compare the
effectiveness of two different approaches to providing routine HIV counseling, testing, and
referral services in an urban hospital emergency department setting. One approach will be
led by an HIV counselor, and the other approach will be led by an emergency department staff
member. For both approaches, the study will evaluate to what extent patients accept HIV
testing, how well follow-up care is established, and the cost-effectiveness of the approach.
Participants in this study will include adults who visit Brigham and Women's Hospital
emergency department in Boston, Massachusetts. Participants will be randomly assigned to a
counselor versus provider and will be asked to fill out a questionnaire while waiting in the
emergency room. The questionnaire will be anonymous. Participants will then be offered an
oral rapid HIV test. Test results will be available in about 20 minutes and will be provided
to participants by either their assigned HIV counselor. Participants who test positive for
HIV will be offered a more definitive blood test to confirm HIV infection. The blood test
results will be available 2 weeks from testing, and participants must return to the hospital
to get their test results. Participants who test positive for HIV will be offered counseling
support and referral services by either their assigned HIV counselor or emergency department
staff member. Follow-up care appointments will also be initiated at this time. For
participants who test positive for HIV, the study will last about 6 months. There will be no
follow-up visits for participants who do not test positive for HIV during their emergency
room visit.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
| Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
| Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
| Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
| Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
| Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
| Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
| Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
| Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
| Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
| Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
| Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
| Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
| Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
| Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
| Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
| Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
| Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
| Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |